ReViral – Innovative therapies for viral diseases ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds. The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.